A cost-benefit analysis of blood donor vaccination as an alternative to additional DNA testing for reducing transfusion transmission of hepatitis B virus

Vaccine

Volumn 28, Issue 49, 2010, Pages 7797-7802

  Fischinger, J M ^a   Stephan, B ^b   Wasserscheid, K ^b   Eichler, H ^b   Gartner B C ^b  

^a St Josef Krankenhaus   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Blood donation; HbsAg; Health economics; PCR; Transfusion

Indexed keywords

HEMOGLOBIN A1C; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; GERMANY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; VIRUS TRANSMISSION;

ADULT; BLOOD DONORS; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; DNA, VIRAL; DONOR SELECTION; FEMALE; GERMANY; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HUMANS; MALE; MODELS, ECONOMIC; QUESTIONNAIRES; VACCINATION;

EID: 78349312993     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.037     Document Type: Article

References (24)

1. Paul Ehrlich Institut. Bekanntmachung der Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) gemäß §§ 12 und 18 des Transfusionsgesetzes (TFG) (Novelle 2005). Bundesanzeiger 2005;209:1576457.
2. Offergeld R., Faensen D., Ritter S., Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Eurosurveillance 2005, 10(2):8-11.
3. Fang C.T. Blood screening for HBV DNA. Journal of Clinical Virology 2006, 36(Suppl 1):S30-S32.
4. Lelie N., Heaton A. Hepatitis B A reveiw of the role of NAT in enhancing blood safety. Journal of Clinical Virology 2006, 36(Suppl 1):S1-S2.
5. Gerlich W.H. Hepatitis-Impfung von Blutspendern: notwendig, machbar, bezahlbar?. Transfusion Medicine and Hemotherapy 2004, 31(6):412-413.
6. Dodd R.Y., Notari E.P., Stramer S.L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002, 42(8):975-979.
7. Schreiber G.B., Busch M.P., Kleinman S.H., Korelitz J.J. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. New England Journal of Medicine 1996, 334(26):1685-1690.
8. Gesemann M., Gentner P., Scheiermann N. Hepatitis B vaccination of blood donors - a cost-benefit analysis. Beiträge zur Infusionstherapie und Transfusionsmedizin 1994, 32:110-112.
9. Hourfar K., Jork C., Schottstedt V., Weber-Schehl M., Brixner V., Michael P., et al. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008, 48(8):1558-1566.
10. Kleinman S.H., Busch M.P. Assessing the impact of HBV NAT on window period reduction and residual risk. Journal of Clinical Virology 2006, 36(Suppl 1):S23-S29.
11. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford. 3rd ed.
12. Konsensus H. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - Revidierte Fassung des Hannoveraner Konsensus. Gesundheitsökonomie & Qualitätsmanagement 1999, 4:A62-A65.
13. Rendi-Wagner P., Kundi M., Stemberger H., Wiedermann G., Holzmann H., Hofer M., et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001, 19(15-16):2055-2060.
14. Van der Wielen M., Van Damme P., Chlibek R., Smetana J., von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine 2006, 24(26):5509-5515.
15. Clemens R., Sanger R., Kruppenbacher J., Hobel W., Stanbury W., Bock H.L., et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance. Vaccine 1997, 15(4):349-352.
16. Banatvala J., Van Damme P., Van Hattum J. Boosters for hepatitis B. European Consensus Group on hepatitis B immunity. Lancet 2000, 356(9226):337-338.
17. Haschberger B., Waterkamp A., Heiden M., Seitz R. Bericht zur Meldung nach §21 TFG für die Jahre 2001 und 2002. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005, 48(1):99-119.
18. Ringwald J., Mertz I., Zimmermann R., Weisbach V., Strasser E., Achenbach S., et al. Hepatitis B virus vaccination of blood donors - what costs may be expected?. Transfusion Medicine 2005, 15(2):83-92.
19. Safari A., Andre F. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999, 18(1-2):57-67.
20. Sugden R., Williams A. The principles of practical cost-benefit analysis 1978, Oxford University Press, Oxford.
21. Weinstein M.C., Fineberg H.V. Clinical decision analysis 1980, WB Saunders Co., Philadelphia.
22. McMahon B.J., Bruden D.L., Petersen K.M., Bulkow L.R., Parkinson A.J., Nainan O., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Annals of Internal Medicine 2005, 142(5):333-341.
23. Impfkommission S. Empfehlungen der Ständigen Impfkommission am Robert-Koch-Institut. Epidemiologischen Bulletin 2006, 30:235-254.
24. Willand L., Ritter S., Reinhard B., Offergeld R., Hamouda O. Infektionsepidemiologische Daten von Blutspendern 2006. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008, 51(8):902-914.